What are Insiders Buying at Market Highs- Week 6-12-20?
Fibrogen CEO Conterno bought 27,800 shares at $35.47. After last year’s unexpected passing of founder and long-time helmsman Thomas Neff, FibroGen needed a permanent successor—and with its big roxadustat launch looming, that new CEO would ideally know the ropes in kidney and metabolic diseases. Conterno, who came from Lilly six months ago as its U.S. business chief and worldwide diabetes lead, became FibroGen’s new CEO, in January. This is his first open market purchase. Here is a link to a recent Goldman Sachs investor presentation According to their website, FGEN is dedicated to creating innovative, first-in-class medicines for the treatment … Read more